Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
Latest Information Update: 13 Aug 2024
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Docetaxel (Primary) ; Niraparib (Primary) ; Prednisone (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms GUNS
- 01 Nov 2021 Status changed from not yet recruiting to recruiting.
- 26 Apr 2021 Planned initiation date changed from 1 Apr 2021 to 1 Jun 2021.
- 26 Mar 2021 New trial record